Stockwinners Market Radar for May 14, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:53 EDT Eisai/Biogen initiate FDA BLA for LEQEMBI - Eisai Co., (ESALY) and Biogen Inc. (BIIB) "announced that Eisai has initiated the rolling submission of a Biologics License Application, BLA to the FDA for lecanemab-irmb, or LEQEMBI, subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. LEQEMBI is indicated for the treatment of Alzheimer's disease in patients with Mild Cognitive Impairment or mild dementia stage of disease The BLA is based on data from the Clarity AD open-label extension and modeling of observed data. If approved by the FDA, the LEQEMBI autoinjector could be used to administer LEQEMBI at home or at medical facilities. The injection process requires less time than the IV formulation. As part of the subcutaneous autoinjector 360 mg weekly maintenance regimen under review, patients who have completed the biweekly IV initiation phase would receive weekly doses that maintain effective drug concentrations to sustain the clearance of highly toxic protofibrils* which can continue to cause neuronal injury even after the amyloid-beta plaque has been cleared from the brain."

19:10 EDT OpenAI co-founder Sutskever to leave company - Ilya Sutskever, co-founder of Microsoft-backed OpenAI, said in a post on X, formerly Twitter, "After almost a decade, I have made the decision to leave OpenAI. The company's trajectory has been nothing short of miraculous, and I'm confident that OpenAI will build AGI that is both safe and beneficial under the leadership of [Sam Altman, Greg Brockman, Mira Murati] and now, under the excellent research leadership of [Jakub Pachocki]. It was an honor and a privilege to have worked together, and I will miss everyone dearly. So long, and thanks for everything. I am excited for what comes next - a project that is very personally meaningful to me about which I will share details in due time."

18:40 EDT Antero Resources CFO Kennedy sells 50,000 common shares - In a regulatory filing, Antero Resources CFO Michael Kennedy disclosed the sale of 50,000 common shares of the company on May 14 at a price of $33.72 per share.

18:36 EDT New York Community Bancorp to sell $5B in warehouse loans to JPMorgan Chase - New York Community Bancorp (NYCB) announced that it has agreed to sell approximately $5 billion in mortgage warehouse loans to JPMorgan Chase Bank (JPMC). Upon closing, the Company expects that the transaction will add 65 basis points to the CET1 capital ratio, as converted for the preferred, resulting in a pro-forma CET1 capital ratio of 10.8% as of March 31, 2024. It will also bolster our liquidity profile as the proceeds of the sale will be reinvested into cash and securities. On a pro-forma basis, the ratio of cash and securities to total assets is projected to improve to 24% from 20% at March 31, 2024. Similarly, the Bank's pro-forma loan-to-deposit ratio is expected to decline to 104% compared to 110% at the end of the first quarter of 2024.

18:25 EDT Stanley Black & Decker CEO sees gross margins increasing - In an interview on CNBC's Mad Money, Donald Allan, Jr. said Stanley Black & Decker will be around 30% gross margins exiting 2024, heading to 32%-35% a year later. As the market gets stronger, the company will be more prepared to take advantage, he added. The dividend is a "really important story" to the company's shareholders, and it will aim to sustain and increase it, he noted. He considers Home Depot (HD) and Lowes (LOW) "incredibly important" customers.

18:01 EDT SLB exec sells $3.04M in common stock - In a regulatory filing, SLB Foods disclosed that its CTO Demosthenis Pafitis sold 63.1K shares of common stock on May 14th in a total transaction size of $3.04M.

17:42 EDT Logitech proposes FY24 dividend boost of CHF 0.10 -CHF 1.16 p/s - Logitech International announced that the company's board of directors has approved a proposal for a Fiscal Year 2024 cash dividend, which, if approved by shareholders, would be an increase of approximately CHF 0.10 to CHF 1.16 per share. This proposed, increased cash dividend demonstrates Logitech's continued commitment to consistently return cash to shareholders. This proposal will be voted on by Logitech's shareholders at the Company's 2024 Annual General Meeting.

17:29 EDT Piedmont Office Realty announces Travel + Leisure lease for new headquarters - Piedmont Office Realty Trust (PDM) announced that Travel + Leisure (TNL) has chosen Piedmont's 501 W. Church building located in downtown Orlando for its new corporate headquarters. Travel + Leisure has signed a new lease for the entirety of the 5-story, approximately 182,000 square foot building through 2040 and will ultimately employ approximately 900 individuals at the property. Piedmont plans to renovate and rebrand the building in anticipation of Travel + Leisure's 2025 commencement, adding signage and modern amenities including a new fitness center, conference center and cafe, to create an office experience tailored for Travel + Leisure's employees.

17:25 EDT EVgo CEO Khan buys over $250K in company shares - The CEO of EVgo, Badar, Khan disclosed the purchase of 125K shares of company stock at $2.01 per share on May 13 for a total transaction amount of $250,750.

17:22 EDT Zapata AI announces strategic collaboration with Tech Mahindra - Zapata announced a strategic collaboration with Tech Mahindra, a global provider of technology consulting and digital solutions to enterprises across industries. The companies will focus on offerings that leverage Zapata AI's suite of quantum-based Generative AI solutions to augment Tech Mahindra's capabilities, seeking to deliver solutions that achieve "Scale at Speed" to drive operational efficiencies and customer responsiveness for global Communication Service Providers. The relationship will provide Zapata AI access to Tech Mahindra's portfolio of global CSPs in order to market and deploy its suite of Generative AI solutions.

17:10 EDT Via Renewables announces Glass Lewis, ISS recommendations for merger pact - Via Renewables announced that independent proxy advisory firms Institutional Shareholder Services, or ISS, and Glass Lewis have both recommended that the company's shareholders vote for each of: the approval of the Agreement and Plan of Merger, dated as of December 29, 2023, by and among the Company, Retailco, a Texas limited liability company, and NuRetailco, a Delaware limited liability company and wholly-owned subsidiary of Parent, pursuant to which Merger Sub would merge with and into the company with the company surviving the merger, following which all of the issued and outstanding shares of the company's Class A common stock, par value $0.01 per share, would be acquired by Parent for $11.00 per share in cash except for the shares of Class A Common Stock held or beneficially owned by the company or any subsidiary of the Company, or (b) William Keith Maxwell, III and any person or entity controlled by Mr. Maxwell, including Parent, Merger Sub and NuDevco Retail, and any holder of record of Class A Common Stock who did not vote in favor of the merger proposal and is entitled to demand and validly demands appraisal of such shares of Class A Common Stock pursuant to, and complies in all respects with, Section 262 of the General Corporation Law of the State of Delaware; and the approval, on a non-binding, advisory basis, of the compensation that may become payable to the company's named executive officers in connection with the merger.

17:04 EDT Copa Holdings reports April passenger traffic up 11.2% y/y - For April 2024, Copa Holdings' capacity increased by 9.6%, while system-wide passenger traffic also increased by 11.2%, compared to 2023. As a result, the system load factor for the month was 86.6%, 1.2 percentage points higher than in April 2023.

17:02 EDT Washington Federal raises share repurchase authorization by 10M - The Board increased the number of shares authorized for repurchase by 10M, bringing the currently authorized amount up to 11.8M shares. Over the last three fiscal years the company has repurchased 12.7M shares at a weighted average price of $31.32, this represents 17% of the shares outstanding on October 1, 2020.

16:57 EDT Lumos Pharma announces results from FDA meeting on LUM-201 - Lumos announced that the FDA indicated that a placebo-controlled trial design is an appropriate option for a Phase 3 trial for LUM-201. The company believes this reflects FDA's recognition of unique qualities of LUM-201's mechanism of action as a growth hormone secretagogue. Proposal for a Phase 3 trial to include a 12-month double-blinded, placebo-controlled design with 2:1 randomization, approximately 150 patients with the placebo-controlled portion of the study lasting six months, which Lumos believes will improve the likelihood of success when compared to a non-inferiority study.Planning is ongoing, and the company expects to initiate a Phase 3 trial of LUM-201 in Q4 2024, subject to FDA approval. "In addition to our encouraging engagement with the FDA, we are also very pleased to share updated data from our Phase 2 OraGrowtH trials. These data continue to show that LUM-201 produces a significant increase in growth from baseline in annualized height velocity (AHV) at 6 and 12 months in per protocol analysis. Combined data also suggest durable benefit out to 24 months. We believe these developments have positioned us to advance LUM-201 toward both a Phase 3 registrational trial and potential approval of LUM-201 as the first oral therapeutic for moderate pediatric growth hormone deficiency," Rick Hawkins concluded.

16:52 EDT Nanobiotix announces FDA issuance of Study May Proceed Letter for NBTXR3 study - Nanobiotix (NBTX) announced that the FDA issued a Study May Proceed Letter for a randomized Phase 2 study evaluating NBTXR3 for the treatment of patients with stage 3, unresectable non-small cell lung cancer. An IND to support this trial was submitted by the global trial sponsor, Johnson & Johnson Enterprise Innovation Inc., a Johnson & Johnson (JNJ) company.

16:49 EDT Synaptics names Ken Rizvi CFO - Synaptics (SYNA) announced Ken Rizvi will join the company as senior VP and CFO, effective July 15. Rizvi will report to Synaptics president and CEO Michael Hurlston and serve on the company's leadership team. He will be responsible for all the aspects of the company's global finance function including accounting, corporate development and investor relations. Ken joins Synaptics from SMART Global Holdings (SGH) where he served as SVP and CFO.

16:40 EDT Northrop Grumman CFO Dave Keffer to retire - Northrop Grumman Corporation announced that Dave Keffer, corporate VP and CFO, has announced his intent to retire, effective February 21, 2025, to spend more time with family. In addition, Mark Caylor, corporate VP and president of Mission Systems, has announced his intent to retire, effective July 26, 2024. The board has elected Kenneth Crews, VP of business management and CFO for the Space Systems sector, to succeed Keffer, effective October 1, 2024. Crews will become VP, Corporate Finance on July 1, and work directly with Keffer to ensure a smooth transition. Effective July 1, Roshan Roeder, corporate VP and president of Defense Systems, will succeed Caylor as president of Mission Systems. The board also has elected Ben Davies corporate VP and president, Defense Systems sector, to succeed Roeder. Davies is currently corporate VP and general manager of the Strategic Deterrent Systems division in Space Systems. The SDS division, which includes the Sentinel program, also will be realigned into Defense Systems effective July 1.

16:22 EDT Procaps Group delays filing Form 20-F - The company stated: "Procaps Group announced that it has determined it is unable to file its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, within the prescribed time period. Additional time is necessary to prepare and complete the Company's review of its financial statements for the year ended December 31, 2023, in order for the Company to file its annual report on Form 20-F, including with respect to an ongoing internal investigation initiated by the Company's Audit Committee with the assistance of external advisors into matters involving the Company's historical accounting treatment and associated financial statement disclosure related to a 2012 loan in the amount of approximately $2.5 million that involved related parties."

16:18 EDT Pulse Biosciences enhances executive leadership team - The company states: "Proven atrial fibrillation medical technology leader Burke T. Barrett has been appointed President and Chief Executive Officer effective immediately. Concurrently, the Company announced the appointment of Kevin Danahy, former President and Chief Executive Officer, as Chief Commercial Officer. Mr. Danahy will now focus his full time leading the pilot launch of the recently FDA cleared CellFX nsPFA Percutaneous Electrode System."

16:14 EDT SGH announces CFO transiction plan - SMART Global Holdings announced that Ken Rizvi, senior vice president and CFO, will depart the Company on June 30, 2024 to pursue another opportunity. Effective upon Mr. Rizvi's departure, Jack Pacheco, the Company's chief operating officer and president of Memory Solutions, and its former CFO, will assume the role of interim CFO while the Company searches for a permanent successor.

16:10 EDT Koru Medical signs supply agreement for Phase 3 trial - KORU Medical is pleased to announce the signing of a Phase III clinical supply agreement for a novel enzyme replacement therapy to treat a rare endocrinological disease. This significant milestone marks the progression of this collaboration, previously announced in July 2023. Since then, the KORU Medical Freedom System successfully passed validation testing to meet the subcutaneous infusion administration specifications for this novel drug. The Phase III trial will evaluate bi-weekly infusions using the Freedom System. If successful in the Phase III trial, this drug would be the first disease-modifying treatment option for the 10,000 patients worldwide afflicted by this rare genetic disease. The drug has been granted Breakthrough Therapy, Rare Pediatric Disease, and Fast Track designations by the FDA, as well as Orphan Drug designation in the US and Europe.

16:08 EDT AEye, Accelight Technologies, LighTekton to partner on LIDAR solutions for China - AEye announced it will partner with Accelight Technologies, Inc. and LighTekton Co., Ltd. to deliver AEye's 4Sight( lidar solutions to the China market. Together, the group will help deliver safer autonomous trucking and railway systems in China, using AEye's ultra-long-range 4Sight platform. ATI is a global company and a manufacturer of passive and active pluggable modules used in fiber optic networks for telecom, datacenter, CATV, and broadband access networks. LighTekton is a high-tech enterprise focusing on photoelectric perception technology in the field of pan-autonomous driving, headquartered in Wuhan Optics Valley. Matt Fisch, AEye CEO said, "China is leading the market in lidar adoption particularly as it applies to the build-out of its smart rail transit and investment in autonomous trucking for its highway system. Our 4Sight platform is an ultra-long-range solution that provides 'safety at speed' and could help deliver greater efficiency and safety for China's dynamic public transportation systems. We are excited to work with two technology leaders to bring our 4Sight platform to China's extensive highway and rail systems. ATI and LighTekton are the right partners to make this happen, with their advanced capabilities and innate desire to deliver a safer experience for both autonomous trucking and railways."

16:03 EDT Curis announces data from ongoing TakeAim Leukemia study - Curi announced updated data from the ongoing TakeAim Leukemia study, or CA-4948-102, in relapsed/refractory, or R/R, AML to be presented at the ASCO and EHA conferences. This update includes data for 25 new patients in the FLT3 mutation, or FLT3m, and U2AF1/SF3B1 Splicing Factor mutation, or SFm, cohorts who had received fewer than 3 lines of prior therapy and were treated with emavusertib as monotherapy at the Recommended Phase 2 Dose, or RP2D, of 300 mg BID. 12 R/R AML patients with FLT3m were treated with emavusertib. Prior therapies included venetoclax, hypomethylating agents or HMA, and FLT3 inhibitors. Preliminary data show 6 objective responses in 11 response-evaluable patients: 3 complete remission, or CR, 1 CR with partial hematologic recovery, or CRh, and 2 morphologic leukemia-free state, or MLFS, with on-treatment duration range of 46-324 days. 4 patients are ongoing at the data-cutoff, including 1 CRh and 1 MLFS. 3 of 3 patients who were naive to FLT3i treatment achieved objective response, 3 of 8 patients who progressed on, or following, prior FLT3i treatment achieved objective response, 1 patient is not response-evaluable. All responders demonstrated complete normalization of blast counts in the bone marrow. One of these patients proceeded to allogenic stem cell transplantation. Responses were achieved rapidly in this population, with 5 of 6 responses occurring within one cycle of treatment.

16:00 EDT Centene's Sunflower Health Plan selected for Kansas Medicaid Award - Centene announced that the Kansas Department of Administration has selected its Kansas-based subsidiary, Sunflower Health Plan to continue providing managed health care services through KanCare, the State of Kansas' Medicaid and Children's Health Insurance Program, CHIP. The new three-year contract is expected to take effect on January 1, 2025, with the option to renew for up to two, 12-month extensions. "We are honored to continue our more than a decade-long history of serving people who depend on Medicaid in Kansas," said Centene Chief Executive Officer, Sarah London. "Looking ahead, we are thrilled to deliver on the State's renewed focus on integrated, whole-person care and innovative strategies to best support members and providers. We look forward to continuing our strong partnership with the state and contributing further to the health and wellness of KanCare members."

14:38 EDT Google says Gemma downloaded 'millions' of times - Says PaliGemma, a new open-source AI model, is available right now. Says Gemma 2, next-generation of Gemma, to be available in June. Gemma is Google's family of open-source models.

14:33 EDT Google says Gemini 1.5 Pro, Flash both available today globally - Says both products to be available in over 200 countries and territories.

14:23 EDT Google says Circle to Search available on over 200M devices by end of 2024

14:11 EDT Google unveils Gems in Gemini App - Says Gems are personal experts that can be tailored to whatever user needs. Says Gems will roll out "in the coming months."

13:56 EDT Google says Gemini for Workspace Side Panel available next month

13:50 EDT Google says introducing multi-step reasoning in Search with AI - Says Gemini AI can help users plan actions and activities in Search in an instant.

13:37 EDT Google unveils Veo, an AI tool for videos - Says Veo will be in VideoFX, meant for creating video prompts.

13:26 EDT Google unveils Project Astra, a universal AI agent - Says Project Astra is meant to be a universal agent for everyday life, and will be the reason why Gemini will be multimodal. Says users can talk to Astra conversationally without lag or delay.

13:20 EDT Relativity Acquisition terminates combination agreement with SVES - Relativity Acquisition Corp. announced that the company had elected to terminate the business combination agreement by and among Relativity and SVES LLC, effective immediately. As a result, the business combination agreement is of no further force and effect, with the exception of certain specified provisions in the agreement, which shall survive the termination and remain in full force and effect in accordance with their respective terms. The Company and its sponsor intend to seek alternative ways to consummate an initial business combination.

13:07 EDT Google to roll out AI Overviews to U.S. customers this week - Says "very early" into AI plans. Says all 2B user products use Gemini AI. Says 1.5M developers use Gemini modles across Google tools. Says will roll out AI Overviews, previously called Search Generative Experiences, to all customers in U.S. this week, coming to more countries "soon." Comments taken from Google I/O Conference Keynote presentation.

12:50 EDT Cerence 'tapping NVIDIA's core expertise' for in-car user experience - A blog posted to Nvidia's (NVDA) website states in part: "The integration of AI has become pivotal in shaping the future of driving experiences. As vehicles transition into smart, connected entities, the demand for intuitive human-machine interfaces and advanced driver assistance systems has surged In this journey toward automotive intelligence, Cerence, a global leader in AI-powered mobility solutions, is tapping NVIDIA's core expertise in automotive cloud and edge technologies to redefine the in-car user experience." Reference Link

12:49 EDT Cerence trading halted, volatility trading pause

12:04 EDT Xponential Fitness falls -7.6% - Xponential Fitness is down -7.6%, or -72c to $8.72.

12:02 EDT IHS Holding falls -14.9% - IHS Holding is down -14.9%, or -57c to $3.27.

12:00 EDT GameStop rises 63.5% - GameStop is up 63.5%, or $19.33 to $49.78.

11:57 EDT T-Mobile sees 500,000 postpaid net adds in Q2 - Comments taken from Moffett Nathanson Technology, Media and Telecom Conference.

11:33 EDT Humana saw 'some incremental positivity' as claims further matured - Speaking at the Bank of America conference, executives from Humana stated in part: "We saw - And we always anticipate positive development into the next year just because of our reserving practices. When we speak about favorability, it means it was more positive than we had anticipated. So, as we said on our first call, we saw positive development primarily for third quarter. We mentioned that if we just let things run it would have suggested positive development for fourth quarter as well. Didn't want that run through the first quarter because of the change. Now that those claims have further matured an additional month, we did see some incremental positivity again all quarters in 2023, but mostly in the fourth quarter."

11:04 EDT Century Aluminum: White House actions 'critical' for U.S. aluminum industry - President Biden announced that his administration would triple existing tariffs on Chinese aluminum imports pursuant to Section 301 of the Trade Act of 1974. Century Aluminum said today's action provides a clear and strong response to China's unfair trade policies and will help to put a stop to China's continuing build-up of overcapacity and non-market pricing actions. Jesse Gary, Century's President and CEO, who attended the White House event announcing the move, praised the President's action: "Today's actions are critical for the U.S. aluminum industry. President Biden's decisive leadership on Sec. 301 tariffs and to invest in the resurgence of U.S. manufacturing, shows this Administration's commitment to U.S. primary aluminum production. Thanks to the President's leadership, Century is planning to build a new greenfield facility that will double existing domestic capacity. The smelter would not only be the first new American aluminum smelter in 45 years, but also one of the "greenest" smelters in the world, powered with cutting edge technology and renewable energy. This Administration announced a $500M grant which will help to facilitate this investment in our future."

11:01 EDT CVS Health: Core trends 'very consistent' with 2023 - Thomas Crowley, the CFO of CVS Health, at the BofA Securities Health Conference, said that the company talked about 55%-60% of earnings occurring in the back half of 2024, and "as I look at consensus, it is at the bottom end of that range." Crowley said he would "think about something in the middle." Consensus is $7.00. The CFO said CVS had some "timing issues" in the first quarter, and as the company thinks about the progression of earnings, "the slope is maybe a little different than what you might have assumed," but that core trends in 2024 are very consistent with what was seen in 2023.

10:26 EDT GSK, Abu Dhabi partner to establi regional vaccine distribution hub - The Department of Health - Abu Dhabi, the regulator of the healthcare sector in the Emirate, has signed a Memorandum of Understanding with GSK to establish a regional vaccine distribution hub in Abu Dhabi. The key pillars of the collaboration are: the establishment of a regional vaccine distribution hub in Abu Dhabi; working together to maximize the strategic and healthcare impacts of the establishment of the GSK Vaccine Regional Distribution Hub; collaborating to ensure its successful establishment and operation; and exploration of opportunities to foster knowledge exchange and capability building through collaboration between GSK and the UAE; and jointly focusing on prevention strategies to address public health challenges. Boyd Chongphaisal, Vice President and General Manager, GSK Gulf, said: "As a global biopharma company, GSK is dedicated to developing transformational vaccines and medicines. With a focus on driving innovation, we aim to positively impact millions of lives across the Gulf countries through strategic partnerships. Through establishing a regional vaccines distribution hub in Abu Dhabi, we will be able to meet the increasing demand for GSK vaccines in the region, Near East and South Asian countries, advancing healthcare standards and addressing public health challenges."

10:14 EDT Gilead's Kite data at EHA 2024 demonstrate 'positive' patient outcomes - Kite, a Gilead Company, announced 12 abstracts from its Chimeric Antigen Receptor T-cell therapy portfolio at the upcoming 2024 European Hematology Association annual Congress, June 13-16, Madrid, Spain. Four presentations will highlight real-world experience with Yescarta, including manufacturing experience for patients with relapsed/refractory large B-cell lymphoma in second-line versus third-line treatment and beyond. The real-world manufacturing analysis investigated potential benefits of administering Yescarta in earlier lines of therapy by assessing manufacturing success rate and product characteristics. Analyses exploring outpatient administration of Yescarta in R/R LBCL includes preliminary results of the Phase 2 ZUMA-24 study to evaluate the safety and efficacy of Yescarta outpatient administration compared to previous in-hospital clinical trials and real-world evidence. A real-world analysis on the use of Yescarta and Tecartu assess safety trends and hospitalization rates following treatment to further understand the feasibility of CAR T-cell therapy administration in the outpatient setting. "Whether it's continuing to evolve our industry-leading manufacturing capabilities or looking at different ways patients can obtain CAR T-cell therapy, such as in the outpatient setting, our goal is to improve patient outcomes and experience with our therapies," said Ibrahim Elhoussieny, Vice President, Medical Affairs, Kite. "These data will reflect our progress in helping CAR T reach more people with complex and hard-to-treat blood cancers."

10:06 EDT Affimed reports acceptance of abstract on AFM28 preclinical data at EHA 2024 - Affimed N.V. announced the publication of an abstract for the annual congress of the European Hematology Association, taking place in Madrid, Spain, June 13 - 16, 2024. The abstract presents preclinical data of Affimed's CD16A/CD123-targeting ICE, AFM28, in an acute myeloid leukemia mouse xenograft model and shows that increasing doses of AFM28 lead to a dose-dependent tumor growth control, resulting in an increased median life span of the treated mice compared to controls. In addition, the abstract shows a data set from a collaboration with Dr. Hind Medyouf's group at the Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt am Main, Germany. In a newly engineered ex vivo Human Organotypic Marrow Environment model, the combination of AFM28 and allogeneic NK cells can lead to an effective reduction of CD123-expressing AML patient-derived leukemic blasts and stem cells. Importantly, the HOME model exhibits key immune suppressive cellular components, i.e. mesenchymal niche cells, enhancing the translational relevance of AFM28 preclinical activity. "The significant anti-leukemic activity of AFM28 observed in in vivo as well as in vitro settings is encouraging," said Dr. Wolfgang Fischer, COO of Affimed. "In combination with the previously demonstrated safety profile in cynomolgus monkeys, these data indicate AFM28's potential to eradicate residual disease in patients with AML in an effective and safe manner."

10:05 EDT Big Lots rises 32.9% - Big Lots is up 32.9%, or $1.22 to $4.93.

10:03 EDT Aerojet Rocketdyne to be propulsion provider for Next Generation Interceptor - Aerojet Rocketdyne, an L3Harris Technologies (LHX) company, will be the propulsion provider for the Missile Defense Agency's Next Generation Interceptor as part of the Lockheed Martin (LMT) team. On April 15, MDA announced it selected Lockheed Martin for NGI, the nation's first line of defense against long-range ballistic missile threats from rogue nations. NGI is part of MDA's Ground-based Midcourse Defense system and will provide a new, advanced interceptor to protect the homeland

10:02 EDT Navios Maritime Partners falls -6.3% - Navios Maritime Partners is down -6.3%, or -$3.08 to $45.58.

10:00 EDT Home Depot says SRS acquisition opens up additional $50B of TAM - Says SRS a "great opportunity" to expand markets, capabilities. Says company is as well positioned on price/value as it has been in "some time." Says "so much share to gain with consumer." Seeing great customer engagement in areas where weather has been favorable. Says organized retail crime "still a problem." Says promotional environment has normalized to pre-Covid levels. Seeing "very stable environment" in commodity inflation.

09:52 EDT Big Lots rises 34.9% - Big Lots is up 34.9%, or $1.30 to $5.01.

09:50 EDT AMC Entertainment rises 121.2% - AMC Entertainment is up 121.2%, or $6.29 to $11.48.

09:48 EDT Alibaba falls -6.1% - Alibaba is down -6.1%, or -$5.15 to $79.45.

09:47 EDT Miniso falls -13.0% - Miniso is down -13.0%, or -$3.30 to $22.05.

09:36 EDT AMC Entertainment trading resumes

09:35 EDT GameStop trading resumes

09:34 EDT Vuzix, Garmin collaborate for nano-imprinted waveguide-based display system - Vuzix Corporation (VUZI) announced that the Company has signed a multi-phase development contract with Garmin (GRMN) for next generation nano-imprinted waveguide-based display system. Under the terms of the contract, Vuzix will develop and deliver in succession, waveguide based optical systems with full custom projection engines, and then ultimately production units. Vuzix capabilities around the design and development of custom waveguide optics with volume production nano imprinting for vision based optical systems will power solutions for Garmin that offer significant cost, form factor, and space savings versus current deployed technologies.

09:32 EDT Fennec Pharmaceuticals trading halted, volatility trading pause

09:31 EDT AMC Entertainment trading halted, volatility trading pause

09:30 EDT Amazon.com says Adam Selipsky to step down as Web Services CEO

09:29 EDT Mitek Systems and Viewpointe partner in check fraud detection - Mitek Systems announced a new partnership with Viewpointe, a managed content services provider for highly regulated enterprises. This strategic partnership will aim to play a key role in combatting fraud for financial institutions. Mitek's Check Fraud Defender is a cloud-hosted consortium that uses patented imaging science, machine learning, and artificial intelligence to quickly analyze data, to help reduce losses associated with check fraud.

09:23 EDT Home Depot sees FY24 CapEx about 2% of sales - Sees FY24: Gross margin of approximately 33.9%; Operating margin of approximately 14.1%; Tax rate of approximately 24.5%; Approximately 12 new stores; Net interest expense of approximately $1.8B. Says 53rd week expected to contribute approximately 30c of diluted earnings per share.

09:19 EDT Celularity announces publication on benefits of placental circulating T cells - Celularity announced that the Journal for ImmunoTherapy of Cancer, a peer-reviewed online journal of the Society for Immunotherapy of Cancer, published data highlighting the potential advantages of Celularity's T-Cell platform for future immunotherapies including chimeric antigen receptor therapies. The data compared CAR-T cells derived from Celularity's proprietary T cell platform with CAR-T cells derived from healthy adult peripheral blood mononuclear cells. CAR-T cells generated from its T-Cell platform retained stemness, maintained longer telomeres, and were more resistant to both exhaustion and immune checkpoint upregulation. Additionally, an attenuated cytokine response was observed without loss of cytotoxicity. This translated into improved and prolonged in vivo efficacy and persistence compared with healthy, adult PBMC-derived CAR-T. "These findings help differentiate the placenta as a source of cells for immunotherapy and demonstrate the valuable potential of our placental platform for allogeneic CAR-T products," said Dr. Robert Hariri, founder, Chairman and CEO of Celularity. "As the field of cellular immunotherapy moves towards delivering 'one-size-fits-all' allogeneic products, the stemness advantages inherent in our platform have the potential to translate into improved persistence and durable activity with an enhanced safety profile, offering promising prospects for developing more effective CAR-T therapies in the future. Moreover, we believe that our placental platform offers a level of scalability and consistency in manufacturing which can significantly impact the economics of delivering these therapies in the future. Through our state-of-the-art manufacturing and technical infrastructure, Celularity can be an ideal development and manufacturing partner in the cellular medicine industry."

09:17 EDT Mullen Automotive announces $150M financing commitment - Mullen Automotive has received a $100 million financing commitment from a family office and has sold up to an additional $50 million of senior secured convertible notes to family offices and high net worth investors. These commitments satisfy the Company's capital needs over the next 13 months. The Company sold such investors $12.5 million in notes on May 14, 2024. With the $150 million funding commitment, the Company has enough cash and cash equivalents to fund operations over the next 13 months for both Mullen and Bollinger Motors, which includes Bollinger Motors B4 vehicle production.

09:16 EDT PowerBand names Xia Zhang CTO, Blake Kirk COO, Sean Severin CIO - Xia Zhang has returned to the company and has been appointed as PowerBand's Chief Technology Officer. Xia was the original software architect of the used car leasing and loan origination platform for MUSA Auto Finance, which PowerBand acquired its initial 60% interest in 2019. Blake Kirk has been promoted to the position of Chief Operating Officer for the Company. Blake was previously VP of Servicing for Drivrz Financial. Sean Severin has been appointed Chief Information Officer for PowerBand, moving from his previous role of CTO.

09:14 EDT PowerBand Solutions appoints Kris Gaerlan to board of directors - PowerBand Solutions announced the appointment of Kris Gaerlan to the Company's Board of Directors. As President of Dallas Lease Returns, Kris has been responsible for innovating the dealership customer experience. The Company also announces that Darrin Swenson has resigned from the Board of Directors of PowerBand, effective immediately.

09:09 EDT Firefly Neuroscience appoints Johnson as Executive Chairman - Firefly Neuroscience announced the appointment of David Johnson as its Executive Chairman upon closing of its planned merger with WaveDancer. Firefly has entered into a definitive agreement and plan of merger with WaveDancer, which has been approved by the stockholders of both companies and both companies are working towards meeting the final closing conditions.

09:08 EDT NeuroSense partners with PhaseV for machine learning in ALS Phase 3 trial - NeuroSense partnered with PhaseV, a causal machine learning company, for clinical trial analysis and optimization, with respect to the planned Phase 3 trial of PrimeC as a treatment for amyotrophic lateral sclerosis, or ALS. As part of the collaboration, PhaseV conducted an independent analysis of NeuroSense's PARADIGM Phase 2b study using a causal ML and predicts a high probability of success in multiple subgroups for the planned Phase 3 trial of PrimeC as a treatment for ALS. The external results provide important insights that will significantly inform study design, patient enrollment and ensure cost-effectiveness. NeuroSense Therapeutics recently reported positive efficacy and safety data from its Phase 2b trial with its lead drug candidate for ALS, PrimeC, and is planning on embarking on a Phase 3 pivotal trial in the next few months. NeuroSense soon plans to submit its End of Phase 2 package to the FDA and EMA, including the updated Phase 3 study protocol.

09:05 EDT TruGolf appoints Doug Bybee as CRO - TruGolf Holdings announced the appointment of Doug Bybee as Chief Revenue Officer. Doug joins from Srixon and Cleveland Golf, where he was the team leader for regional and strategic channels. Prior to this, Doug was the vice president of sales and business development for USA and Canada at golf technology company Uneekor, where he helped build the foundational pillars for the company's success - from reseller networks and customer support to logistics and fulfillment.

09:04 EDT Jakks Pacific partners with Dav Pilkey to create 'Dog Man' toys, costumes - JAKKS Pacific and its costume division, Disguise, have partnered with Dav Pilkey to create a line of toys and costumes based on Pilkey's bestselling Dog Man graphic novel series and the upcoming Dog Man theatrical release from DreamWorks Animation and Universal Pictures. The license, which includes North America, U.K. and Australia, was brokered by The Joester Loria Group, exclusive global licensing agent for Dog Man and Cat Kid Comic Club, on behalf of Writers House and Dav Pilkey. JAKKS will launch a range of Dog Man products, including plush, action figures, playsets, costumes, and costume accessories in early 2025 to coincide with the Universal Pictures release of the animated Dog Man feature film slated to open in theaters worldwide in January 2025.

09:01 EDT Charles Schwab reports total client assets were $8.85T as of month-end April - The Charles Schwab Corporation released its Monthly Activity Report . Company highlights for the month of April 2024 include: Total net new assets brought to the company by new and existing clients in April 2024 totaled $10B, while core net new assets equaled $1B. These flows reflect client cash disbursements during tax season. Total client assets were $8.85T as of month-end April, up 16% from April 2023 and down 3% versus March 2024. Transactional sweep cash declined by 3% to end April 2024 at $387.7 billion. This month-over-month drawdown was driven by several anticipated factors, including client tax disbursements and seasonal advisory fee payments. Last weekend, Schwab successfully completed the final Ameritrade client conversion, marking the completion of a historic integration. We are pleased to report that the client account and asset conversion went smoothly. The company will share additional perspectives on this tremendous milestone during its Institutional Investor Day scheduled for Wednesday, May 22.

09:00 EDT SRIVARU completes EMC/EMI testing for PRANA 2.0 - SRIVARU Holding announced that its flagship model, the PRANA 2.0, has completed Electromagnetic Compatibility and Electromagnetic Interference testing, marking a significant milestone in the vehicle's development and regulatory compliance process. The PRANA 2.0 is currently undergoing testing requirements mandated by the Central Motor Vehicles Rules. The completion of EMC/EMI testing marks a pivotal advancement in this regulatory process. EMC/EMI testing ensures that electronic devices and systems, including electric vehicles, comply with regulatory standards regarding electromagnetic emissions and susceptibility. Achieving compliance in this area is particularly significant for electric vehicles like the PRANA 2.0, where the integration of advanced electronics and electrical systems is fundamental to its operation and performance.

08:56 EDT ECD Automotive Design delivers Project Red Phoenix to Colorado - ECD Auto Design delivers Project Red Phoenix to its new Colorado home. The new 110 Defender is planned to see plenty of adventure from towing a trailer for family camping trips to trekking up the Colorado mountains and with its LS3 430 HP 6.2L engine, Project Red Phoenix will pack plenty of power to take on any challenge. To further enhance its capabilities, the vehicle is outfitted with a 6-point external roll cage, top mounted spotlights, ladder, and 10,000 lb. capacity winch mounted on the front bumper.

08:54 EDT NanoVibronix in distribution pact with VA supplier CB Medical for UroShield - NanoVibronix announced that it has entered into a distribution agreement with CB Medical or CB Medical for the sale and distribution of the Company's UroShield. Brian Murphy, Chief Executive Officer of NanoVibronix, Inc., commented, "This new agreement provides us with another distribution channel for UroShield within the VA system of providers. CB Medical has a national presence and is committed to helping veterans and active-duty members gain access to beneficial treatments. With millions of urinary catheters used both in and outside of hospitals every year, the risk of infection can be high. UroShield not only prevents infection but can also reduce the pain associated with urinary catheters. We are pleased to be able to add UroShield to CB Medical's catalog for the benefit of veterans and to advance our efforts towards achieving broader distribution."

08:50 EDT Silo to participate in FDA meeting on therapeutic interest in Ketamine - Silo Pharma announced its planned attendance at a hybrid public meeting on June 27, 2024, hosted by the U.S. Food and Drug Administration, FDA, in partnership with the Reagan-Udall Foundation for the FDA. The in-person and virtual event, titled "Understanding Current Use of Ketamine for Emerging Areas of Therapeutic Interest," will explore the landscape for ketamine usage and increasing public interest in ketamine as a treatment for conditions such as depression and chronic pain.

08:49 EDT Ocean Power demonstrates counter unmanned underwater vehicle capability - Ocean Power Technologies announced it has completed successful demonstrations of a Counter Unmanned Underwater Vehicle, CUUV, WAM-V capability. Recent demonstrations at the Navy League's Sea Air Space Exhibition and the Association for Uncrewed Vehicle Systems International's Pacific Pivot Event successfully showcased the ability to detect multiple underwater threats, including, singular and swarming micro Autonomous Underwater Vehicle, AUV.

08:48 EDT Siyata Mobile announces new orders totaling over $2.2M - Siyata Mobile has received new orders for its SD7 handsets and related accessories valued at over $2.2 million in the aggregate. The company also announced that another leading U.S. wireless carrier has designated Siyata's SD7 handset with 'stocked' status, further supporting sell-through of the handsets with promotions and attractive pricing options for end customers. SD7 handsets are now designated as 'stocked' status with three of the four largest U.S. wireless carriers.

08:44 EDT Fortress Biotech announces first patient dosed in Phase 2 study of triplex - Fortress Biotech announced that the first patient was dosed in a multi-center, placebo-controlled, randomized Phase 2 study of Triplex, a vaccine for control of cytomegalovirus, CMV, in patients undergoing liver transplantation. The trial is funded by a grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases, NIH/NIAID, to University of Washington Seattle. This grant has provided $9.0 million to date with an estimated additional $12 million over the next four years in support of the Phase 2 clinical trial. The trial will be conducted in up to 20 nationally recognized transplant centers in the United States. Triplex was initially developed by City of Hope, a world-renowned cancer treatment and research organization, and exclusively licensed to Helocyte.

08:43 EDT Adeia enters into license renewal with Mitsubishi Electric - Adeia (ADEA) announced that Mitsubishi Electric (MIELY), the Japanese multinational electronic and electrical equipment manufacturing company, has agreed to renew its license for access to Adeia's media intellectual property portfolio. This license covers connected TVs produced by Mitsubishi for distribution to businesses and consumers in the Japanese market. "Mitsubishi has maintained a leadership position in Japan's consumer electronics industry for over a century," said Dr. Mark Kokes, Adeia's chief licensing officer and general manager of media. "Adeia's licensing agreement with Mitsubishi underscores the strength of our media IP portfolio in Japan's vibrant and constantly evolving market."

08:41 EDT Portillo's partners with Lou Malnati's for Italian Beef Week - In celebration of Italian Beef Week, Portillo's is reuniting with fellow Windy-City giant, Lou Malnati's to give fans nationwide the opportunity to savor the most Chi-conic culinary collab of all time: the Portillo's x Lou Malnati's Italian Beef Deep Dish. As any Windy City sports fan can tell you, there is nothing sweeter than a "three-peat" - especially one that teams up two masters of Chicago-style cuisine. Once again available for nationwide shipping through Lou Malnati's Tastes of Chicago, the Portillo's x Lou Malnati's Italian Beef Deep Dish Pizza, with either Portillo's homemade sweet peppers or its hot giardiniera for a spicy kick, returns for a limited time in packs of two, four or six, and in combination with other classic Portillo's offerings, like Italian Beef Sandwiches and Chicago-Style Dogs.

08:39 EDT SaverOne 2014 granted European patent for safety transportation market - SaverOne 2014 announced the award of a new patent to the Company by the European Patent Office. The patent, numbered EP3158718, is entitled 'System and Methods to Facilitate Safe Driving'. This newly granted patent encompasses SaverOne's innovative system and groundbreaking methods that employ machine learning and channel fingerprinting techniques. These core technologies provide selective blocking that are designed to restrict certain functions of the driver's mobile phone while preserving full operation of other mobile devices within the vehicle. This targeted approach ensures that specifically the driver of the car is not distracted by his cellphone which is a major cause of accidents, enhancing the safety of all road users. With the addition of this patent, SaverOne's portfolio now includes 23 patents, comprising 11 granted patents and 12 pending patent applications. These patents are filed in key markets such as the US, China, Israel, the United Kingdom, and the European Union, reflecting the Company's strategy for global expansion.

08:37 EDT Nuvei board recommends shareholder vote in favor of going private transaction - Nuvei has filed and is in the process of mailing a letter and management proxy circular to shareholders in connection with its transaction to be taken private by Advent International. The special meeting has been called to consider a special resolution involving the company and Neon Maple Purchaser, a newly-formed entity controlled by Advent which will acquire all the shares of the company that are not held by Philip Fayer, certain investment funds managed by Novacap Management and CDPQ for $34.00 cash per share. The board recommends that shareholders vote for the Arrangement Resolution, after the unanimous recommendation of a special committee of the Board. The consideration represents a premium of approximately 56% to the closing price of the shares on Nasdaq on March 15, and a premium of approximately 48% to the 90-day volume weighted average trading price per Subordinate Voting Share as of such date. The Special Committee concluded that the consideration, which represents an increase of approximately 42% from the consideration initially proposed by Advent, was the highest price that could be obtained from Advent. The cash consideration provides immediate liquidity.

08:35 EDT Owlet receives UK medical device certification for Dream Sock - Owlet has received UK medical device certification, following the recent achievement of CE Mark certification. This marks a milestone for Owlet, moving the company forward in its mission to increase access to medical-grade infant monitoring technology to parents and caregivers around the world. The UKCA certification, granted by a recognized UK-approved body, follows the recent announcement of Owlet's EU CE mark certification of Dream Sock earlier this month and now provides Owlet with medical device certifications in key UK and European markets where its distribution partners operate. These certifications also follow the company's marketing authorizations from the FDA, for Dream Sock, with new medical technology for healthy infants over-the-counter without a prescription, and for BabySat, a prescription-only pulse oximeter designed for use with babies that have a pre-existing medical condition.

08:34 EDT Genprex doses first patient in Acclaim-3 clinical study of Reqorsa - Genprex announced that the first patient has been enrolled and dosed in the company's Phase 1 dose escalation portion of the Acclaim-3 clinical study of Reqorsa Immunogene Therapy in combination with Genentech's Tecentriq to treat patients with extensive-stage small cell lung cancer. The company expects to initiate the Phase 2 expansion study in the second half of 2024

08:29 EDT SOBR Safe signs agreements with two new behavioral health customers - SOBR Safe has signed hardware/software agreements with Lighthouse Recovery Resources and Mountain House Recovery. SOBRsafe has now secured 20 new accounts in 2024, compared to three accounts booked in all of 2023.

08:27 EDT Aptevo Therapeutics announces presentation at PEGS conference - Aptevo Therapeutics announced a presentation at The Essential Protein & Antibody Engineering Summit conference in Boston MA. The session, being offered today, Tuesday May 14, 2023 at 8:30 AM Eastern time and entitled "Development of Target Activated ADAPTIRs for Tumor Immunotherapy," will be led by Dr. Peter Pavlik, PhD, Senior Director of Protein Engineering at Aptevo and will focus on the strategic deployment of early functional screening of a diverse group of binding domains against a given target, combined with screening in multiple possible final formats to elicit varied functional activity, exemplified by preclinical and clinical data supporting predictive outcomes. Aptevo continues to add to a growing body of clinical evidence that supports the preclinical predications of safety, conditional activation, and clinical activity of its portfolio of assets. Recent news from the Company's two clinical programs includes: A heavily pretreated breast cancer patient, enrolled in the ALG.APV-527 Phase 1 open-label, multi-center, multi-cohort trial for the treatment of multiple solid tumor types, entered the trial and improved from progressive disease to long-lasting stable disease while on therapy. The patient has remained on study for more than eleven months and been successfully transitioned to a higher dose level, with no new adverse events since the transition, which may allow for increased clinical benefit. The trial is more than 50% enrolled and we are dosing cohort 5. The Company is on track to initiate part 1 of its upcoming dose optimization trial in 2Q 2024. The study will further evaluate APVO436 for the treatment of acute myeloid leukemia. Aptevo has partnered with premier CRO, Prometrika, for the upcoming study. The first part is a dose optimization trial evaluating standard of care venetoclax + azacitidine along with APVO436 as a frontline treatment for AML patients. It is planned as an open-label, multi-center, multi-cohort study. The trial will evaluate safety/tolerability and efficacy of the triplet combination at multiple dose levels.

08:26 EDT Strata Skin surpasses 100 domestic installations of TheraClear X devices - STRATA Skin Sciences announces its installed base of TheraClear(R)X devices surpassed 100 at the end of the first quarter of 2024. "We continue to grow our domestic installed base of TheraClear(R)X devices quarter by quarter," commented STRATA CEO Dr. Dolev Rafaeli. "As with our much more established XTRAC(R) offering, dermatologists recognize the value of our comprehensive program in treating acne, which is the most common skin condition in dermatology. TheraClear(R)X addresses many of the limitations of existing acne therapies, and its effectiveness is often visible after just a few treatments. Its unique photo pneumatic technology combines vacuum with pulsed broadband light that works both mechanically and thermally on the active acne lesion. With TheraClear(R)X, dermatologists now have a reimbursable option to treat acne, improving the economics for their practice. We look forward to working closely with our customers/partners to continue to increase our domestic install base and reporting on those outcomes in the coming quarters."

08:24 EDT Mondelez to showcase 'sweet' collaborations at Sweets & Snacks Expo - Mondelez International will showcase key innovations and tasty collaborations to accelerate brand loyalty and growth at the 2024 Sweets and Snacks Expo in Indianapolis, IN, on May 15. Among many highlights, the company will present an educational session on proven strategies to help snacking companies success in omnichannel, delivered by Francesca Hahn, U.S. Vice President of Digital Commerce. The company's long-term strategy is powered by a transformation of its marketing and sales capabilities to drive customer and consumer loyalty while accelerating sustainable growth. Mondelez continuously reinvests in its brands to drive marketing and sales excellence, advancing digital-enabled personalization and customer centricity. The company's brands are central in the lives of consumers, and Mondelez is capturing these unique human emotions through personalized outreach campaigns. Hahn's presentation will draw on key learnings from Mondelez's previously announced investment of $1 billion to become the digital snacking leader by 2030 - leveraging data to better inform the company of consumer behaviors and translate these insights into action. With online shopping becoming the norm, convenience and accessibility are driving forces behind snacking trends. The company's annual State of Snacking report reveals the importance of digital experiences in today's snacking sector, with consumers increasingly engaging in online research and on social media to discover new snacks. The message is clear -- snacking remains a consistent daily ritual, and Mondelez continues to innovate and meet consumers where they are to engage. Accordingly, as part of this year's Expo, Mondelez will showcase innovation and tasty new collaborations designed to surprise and delight consumers while staying a step ahead of emerging trends. While the company's iconic brands have been around for decades, Mondelez continues to innovate each year, propelling fresh consumer interest, building on brand loyalty and fostering growth. The OREO brand has teamed up with the SOUR PATCH KIDS brand for an unexpected mix of iconic brands to create the ultimate sweet and sour combination. Available now, Limited Edition Sour Patch Kids flavored OREO cookies with sour sugar inclusions in the creme bring an amazing sweet yet sour cookie pairing, together with an exclusive line of special merchandise for consumers to enjoy.

08:21 EDT American Oncology Network announces date change for Q1 earnings release - American Oncology Network will change the release date of its first quarter 2024 financial results to Monday, May 20, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time the following day.

08:21 EDT Franklin Electric appoints Ruzynski as CEO, Sengstack remains Chairperson - Franklin Electric (FELE) announced that its Board of Directors has appointed Joe Ruzynski as Chief Executive Officer and a member of the Board, effective July 1, 2024. Gregg Sengstack, who has served as CEO since 2014 and Chairperson since 2015, will continue as Executive Chairperson. Ruzynski joins Franklin Electric from nVent Electric plc (NVT), a global leader in electrical connection and protection solutions, where he served as President of the Enclosures Segment since 2018.

08:19 EDT Arcadia Biosciences sells RS Durum Wheat trait to Corteva for $4M - Arcadia Biosciences (RKDA), a producer and marketer of plant-based health and wellness products, announced it has sold its non-GMO Resistant Starch RS Durum Wheat trait to longtime partner Corteva (CTVA) Agriscience. Under the terms of the agreement, Arcadia will receive $4M and retain the right to continue using Resistant Starch Durum in its GoodWheat portfolio of wheat products, including pastas and mac & cheese. Corteva will acquire 24 RS Durum patents in 20 countries. "Wheat is a staple crop worldwide, and consumers are looking for ways to enhance their nutrition through natural sources. As a leading global agricultural company, Corteva is an ideal partner to bring this trait to farmers globally," said Stan Jacot, president & CEO of Arcadia. "This transaction enables our long-standing collaboration to continue, with Corteva eventually supplying seed that farmers could grow for the GoodWheat brand, while the financial component strengthens our balance sheet, allowing us to pursue strategic transactions."

08:18 EDT 89bio initiates Phase 3 ENLIGHTEN-Cirrhosis trial - 89bio announced the initiation of ENLIGHTEN-Cirrhosis, a Phase 3 trial of pegozafermin in patients with MASH with compensated cirrhosis. "MASH patients with compensated cirrhosis are in critical need of effective therapies that can halt and ideally reverse the progression of fibrosis to prevent the onset of liver decompensation," said Arun Sanyal, MBBS, M.D., Director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University. "Due to its demonstrated anti-fibrotic benefits, pegozafermin has the potential to be uniquely positioned to meet the needs of compensated cirrhotic MASH patients and could reduce the risk of decompensation. I look forward to evaluating the potential benefits of pegozafermin in this Phase 3 trial given the severity of symptoms this patient population experiences."

08:16 EDT BranchOut Food signs long-term lease for production facility in Peru - BranchOut Food has signed a long term lease for a 50,000 square foot production facility in Peru. Under the terms of the agreement, BranchOut Food has the first right to purchase the facility at a fixed price at any point during the 10-year term. The Company has expanded its operations in Peru and moved to 100% vertical integration in response to consistent and increasing demand for its branded and white-label products from some of the largest retailers in the US. "Our current large-scale, continuous throughput dehydration machine will be moved into our new space. In addition, our second machine, which is currently on order, will be shipped to Peru and installed in the next couple months. Our new facility will be 100% owned and operated by BranchOut. We estimate the facility has $40 million in production capacity, with additional space to grow as needed," stated Eric Healy, CEO of BranchOut Food. "We are very proud of our significant growth over the last 12 months, which has included repeat orders from the nation's largest warehouse club and the nation's largest retailer, among other retailers across the country. Establishing our own production facility in Peru, one of the world's most abundant fruit and vegetable growing regions, will allow BranchOut Food to control every step of the production process, including quality control, planning, and cost of goods. Additionally, we expect gross margins to grow to 40-50% as our production capacity increases."

08:14 EDT Esperion receives five year patent extension for bempedoic acid - Esperion announced today that the U.S. Patent and Trademark Office, USPTO, issued a U.S. Patent Term Extension, PTE, certificate for bempedoic acid, which is contained in NEXLETOL Tablets and NEXLIZET Tablets. The certificate extends the term of U.S. Patent No. 7,335,799 by five years through December 3, 2030. The PTE certificate was granted under the patent restoration provisions of the Drug Price Competition and Patent Term Restoration Act of 1984. This PTE will be listed in Approved Drug Products with Therapeutic Equivalence Evaluations, published by the U.S. Food and Drug Administration.

08:11 EDT Enveric in $66.5M non-binding deal with MindBio to outlicense NPP candidates - Enveric Biosciences announced that it has signed a non-binding term sheet to out-license a class of Novel Psilocin Prodrugs or NPP, to Vancouver, BC-based MindBio Therapeutics a clinical stage biopharma company, which is pioneering novel treatments for psychiatric conditions using microdoses of psychedelic medicines. ... Pursuant to the terms of the non-binding term sheet, MindBio will seek to advance a drug candidate from the NPP class for neuropsychiatric indications such as depression. The term sheet states that upon entering into a definitive agreement, MindBio would receive an exclusive, global license to the formulations, drugs, method of use, and devices developed to utilize the compound from Enveric and would assume responsibility for all future preclinical, clinical, and commercial development on a royalty-bearing basis for all human and animal pharmaceutical applications. If a definitive agreement is entered into and certain conditions are met, MindBio would pay Enveric development and sales milestones up to an aggregate $66.5M and royalties on all future sales. The license would include the right to sublicense and cash buyout options.

08:04 EDT Dare sees R&D expenses for future quarters lower than Q1 R&D expenses - Research and development expenses: $3.3 million in 1Q-2024 as compared to $5.0 million in 1Q-2023, a 34% decrease compared to Q1-2023. Close-out expenses related to the Phase 2b RESPOND clinical study of Sildenafil Cream and other clinical studies conducted in 2023 contributed significantly to Dare's 1Q-2024 R&D expenses, which will not be the case in future quarters. Until Dare commences a Sildenafil Cream Phase 3 clinical study, Dare expects R&D expenses for future quarters to be lower than its 1Q-2024 R&D expenses.

08:01 EDT LiqTech and Franman sign agreement for water treatment solution in Greece - LiqTech and Franman, a maritime representative to the shipping industry, entered into a partnership agreement for Franman to market LiqTech's marine scrubber water treatment solutions within Greece, the largest ship owning market in the world. Established in 1991, Franman provides a range of equipment, parts, products and services to the shipping industry. LiqTech has developed a marine scrubber water treatment system for both closed-loop and hybrid scrubbers that outperforms discharge limits regulated by the IMO Marpol VI.

07:58 EDT Syra Health named subcontractor in 10-year $43B Defense Health Agency contract - Syra Health has been named a subcontractor for Luke, a prime contractor on a 10-year $43B Defense Health Agency Indefinite-Delivery, Indefinite-Quantity contract, for the Medical Q-Coded Support and Services - Next Generation Program, to provide medical staffing services at DHA facilities across the country. Luke has been awarded all areas of responsibility for staffing five Defense Health Agency labor markets including physicians, nurses, dentists, ancillary services, and medical support personnel. In support of the contract's execution, Syra Health will serve as a subcontractor for Luke and help perform the required services including providing contract workers across various healthcare labor categories in support of mission requirements within DHA hospitals, clinics, dental facilities, and health activities in the 50 United States, D.C., Puerto Rico, Guam, and U.S. territories and possessions. The contract is expected to run from June 2024 until May 31, 2034. Task orders - some of which are anticipated to be received before year's end - will determine the portion of contract revenue for Syra Health. This is Syra Health's second federal government contract announcement.

07:52 EDT Alta Global acquires digital marketing platform Hype, terms not disclosed - Alta Global Group announces its strategic acquisition of Hype for an undisclosed sum. Hype, previously funded by venture capital, had invested over $22M in launching the Hype platform, creating a highly scalable digital marketing platform recognized for its remarkable product suite to help small businesses throughout the world grow in today's age of social media. This innovative product seamlessly blends the functionalities of a mobile website builder, such as Linktree, with core email and SMS marketing capabilities of CRM systems like HubSpot, alongside an integrated payment system. Notably, this mobile-first solution caters perfectly to owner-operators who manage much of their business on their phones, ideal for combat sports gyms. Hype reimagines the future of multiple product categories simultaneously across a $100B+ market for small business software. Hype has processed over $40M in payments through its platform, helped businesses collect over 4 million contacts and is currently generating approximately $200,000 per annum in recurring revenue. Hype's state-of-the-art technology offers user-friendly tools tailored to boost revenue streams, particularly beneficial for small businesses like combat sports gyms. By integrating this technology into its existing platform, Alta estimates this transaction could accelerate its technology roadmap by at least 18 months, delivering many millions of dollars in technology capex and development cost savings, while reducing customer acquisition costs for Alta partner gyms. Alta intends to distribute the Hype product offering across its extensive community of over 500 partner gyms and thousands of coaches and athletes globally across the Alta Platforms. We believe this acquisition presents a significant opportunity to launch a new SaaS offering for our gym, coach, and talent partners, further increasing the embedded revenue opportunity that exists from each gym, coach and talent relationship on our platform. Alongside Alta's existing product offering, the Hype products are expected to accelerate Alta's penetration into the substantial martial arts and combat sports market, with over 45,000 martial arts and combat sports academies in the US alone.

07:50 EDT ARway announces launch of ARway V3.1 - ARway.ai announced the launch of ARway V3.1, a major update to its spatial computing platform providing augmented reality navigation and immersive experiences. The new V3.1 technology updates and features include major improvements to the range and accuracy of AR experiences across large scale venues and increased speed of deployment of AR indoor navigation experiences. The company believes these major improvements will drive additional revenue and additional global deployments ARway.ai currently has over 5000+ total accounts, with 5400+ maps created and 60+ pilots and trials. Demand for ARway is accelerating in from around the world for various use-cases and industries looking to leverage the Company's augmented reality and spatial computing technology.

07:49 EDT Fury Gold Mines updates mineral resources at Eau Claire - Fury Gold Mines provided an updated Mineral Resource Estimate for the high-grade Eau Claire deposit as well as a Maiden Mineral Resource Estimate for the Percival deposit located in the Eeyou Istchee Territory of the James Bay region of Quebec. The Eau Claire project now contains a combined mineral resource of 1.16Moz gold at a grade of 5.64 g/t Au in the Measured and Indicated category as well as an additional 723koz gold at a grade of 4.13 g/t Au in the Inferred Category. Gold mineralization remains open for expansion in all directions at both the Eau Claire and Percival deposits through additional drilling. Highlights: 2024 Updated Mineral Resource Estimate: Addition of 307koz Au in the Measured and Indicated category and 223koz Au in the Inferred category. Eau Claire Resource remains open for further expansion through additional drilling. Eau Claire vein geometry steepened in areas with new data and interpretation. Percival is one of 15+ anomalies along the Percival - Serendipity trend. "Today, we are excited to announce our updated Eau Claire Mineral Resource Estimate. These results are the culmination of three years of work that was focused on adding gold ounces and proving out a substantial high-grade gold resource with excellent infrastructure in the James Bay region of Quebec," commented Tim Clark, CEO of Fury. "As a recap, we have continued to identify significant potential for new discovery across our broader property, which includes a thirty-kilometer section of the Cannard Deformation Zone. Fifty kilometers to the north, we have also acquired 100% of the Eleonore South property, which is strategically positioned adjacent to Newmont's operating Eleonore Mine, one of the top-producing gold mines in Canada. In the coming weeks, we will be reporting results from our early 2024 spring program on our Eleonore South property, as well as an additional planned exploration program for 2024."

07:46 EDT ETFS Capital calls on WisdomTree to run a strategic process - ETFS Capital Limited, the largest combined owner of common stock, $0.01 par value and Series A Non-Voting Convertible Preferred Stock of WisdomTree (WT), with ownership of approximately 10% of the outstanding Common Stock, which together with its Series A Preferred Stock would represent approximately 18% of the Company's outstanding Common Stock on an as-converted basis, responded to the board of directors' of WisdomTree May 13, 2024 letter to stockholders. ETFS said, "In its attempts to avoid being held accountable by stockholders for WisdomTree's unsuccessful attempts to transform the Company into a decentralized finance company, the Board has resorted to a familiar playbook - distract attention from the Company's failure to unlock the value of the core ETF business, deny stockholders access to the KPIs required to judge DeFi initiatives, and demonize ETFS Capital and Graham Tuckwell. The Board's refusal to run an independent strategic review process is the reason ETFS Capital was compelled to launch this campaign. If the Board commences a strategic review, as outlined below, then ETFS Capital intends to suspend its campaign. The Company's upcoming 2024 Annual Meeting of Stockholders is a simple referendum on the Company's ill-advised diversification strategy. The Board continues to deprive stockholders of any meaningful performance insights into WisdomTree Prime and other DeFi initiatives in our view, and is now refusing to unlock value through an independent strategic review process. The focus of ETFS Capital's campaign is NOT about removing or replacing long tenured directors, Win Neuger, Anthony Bossone or the CEO, Jonathan Steinberg, as the Company would have stockholders believe. Instead, the focus of ETFS Capital's campaign is about unlocking value for all Stockholders, which the Board, led by Messrs. Neuger, Bossone and Steinberg, refuses to take the necessary actions to do. We believe the Board has demonstrated that it will only act when stockholders compel them to and that is why this vote is so important. As ETFS Capital outlined in its May 6, 2024 letter to fellow stockholders, it believes that WisdomTree's ETF business is worth $2.1 to $3.0 billion to common stockholders - significantly more than the Company's market value...ETFS Capital is aligned with its fellow stockholders and its request is a simple one: The Board should form a special committee of truly independent directors with a mandate to consider strategic alternatives including, but not limited to, a sale of part or all of the business and returning capital to stockholders, and a significant repositioning of the business including the replacement of members of WisdomTree's senior leadership team. To assist in this work, ETFS Capital further proposes that the special committee retain a recognized tier-one investment bank along with counsel, both of whom are also truly independent. ETFS Capital is urging stockholders to join it in voting AGAINST the re-election of the Chairman Win Neuger, Director Anthony Bossone, and CEO and Director Jonathan Steinberg to send a clear message to the Board - that WisdomTree should hire a reputable banker and evaluate all options to unlock value as soon as possible."

07:42 EDT China's CDE accepts Zai Lab sBLA for efgartigimod alfa injection for CIDP - Zai Lab announced that the Center for Drug Evaluation CDE of the China National Medical Products Administration NMPA has accepted the supplemental Biologics License Application sBLA or efgartigimod alfa injection for the treatment of chronic inflammatory demyelinating polyneuropathy . The CDE granted priority review on May 11, 2024 and Breakthrough Therapy Designation for efgartigimod SC for the treatment of patients with CIDP on September 18.."The sBLA acceptance with priority review designation brings us one step closer to providing a treatment option for patients with CIDP in China, a serious disease that affects approximately 50,000 diagnosed patients, with only a small fraction of patients able to achieve remission on corticosteroids and intravenous immunoglobulin treatment, the current standard of care. Achieving this milestone helps demonstrate our capabilities and commitment to develop and deliver meaningful and differentiated therapies to patients in China with our partner argenx," said Dr. Harald Reinhart, President and Head of Global Development, Neuroscience, Autoimmune & Infectious Diseases, Zai Lab. "Our collaboration with argenx is generating a robust pipeline of indications with the potential to improve care for many patients who live with autoimmune diseases, including CIDP."

07:39 EDT NHTSA opens probe into Waymo over 'unexpected behavior' of self-driving vehicles - The NHTSA is opening an investigation into the performance of Alphabet's Waymo vehicles after reports of its robotaxis exhibiting driving behavior that potentially violated traffic safety laws. The preliminary evaluation into an estimated 444 Waymo vehicles follows 22 reports of 22 incidents including 17 collisions, the NHTSA said. The agency said in some of those cases the automated driving systems "appeared to disobey traffic safety control devices" and some crashes occurred shortly after the automated driving systems "exhibited unexpected behavior near traffic safety control devices." Reference Link

07:38 EDT Absci sees cash runway into 1H27 - Absci continues to expect a gross use of cash, cash equivalents, and short-term investments of approximately $80 million for the fiscal year ending December 31, 2024. This amount includes the expected costs associated with completing the IND-enabling studies for ABS-101 with a third-party contract research organization. Absci continues to focus its investments and operations on advancing its internal pipeline of programs, alongside current and future partnered programs, while achieving ongoing platform improvements and operational efficiencies. Based on the company's current plans, Absci believes its existing cash, cash equivalents, and short-term investments will be sufficient to fund its operations into the first half of 2027.

07:37 EDT Calliditas Therapeutics: Everest Medicines launches Nefecon in China - Calliditas Therapeutics announces that its partner, Everest Medicines, has launched Nefecon in China. Nefecon was awarded conditional approval in IgAN by China's National Medical Products Administration in November 2023. In addition to being approved and commercially launched in Mainland China, Nefecon has also received approval in Macau, Hong Kong and Singapore, and was successfully commercially launched and first prescribed in Macau at the end of last year. New Drug Applications for Nefecon were also successfully accepted for review in Taiwan and South Korea at the end of 2023.

07:35 EDT Crown Castle shareholder Boots Capital's nominees recommended by Glass Lewis - Crown Castle shareholder Boots Capital Management announced that independent proxy advisory firm Glass Lewis has recommended that Crown Castle shareholders vote on Boots Capital's Gold proxy card "for" the election of Boots Capital nominees Ted Miller and Charles Green, and "Withold" from Crown Castle's nominees Cindy Christy and Ari Fitzgerald in connection with Crown Castle's Annual Meeting to be held on May 22. In its report, Glass Lewis concluded that Boots Capital has "put forth a credible slate of nominees, as well as reasonable suggestions for the Company that we believe should earnestly warrant greater consideration by the Board" and there is "room for improvement at the Board level" at Crown Castle. In making its recommendation, Glass Lewis noted: "We believe shareholders should support the election of Dissident Nominees Miller and Green, both of whom are former executives of the company and appear to us to have extensive operational and execution experience in the tower industry...One-third of the company's board still comprises long-tenured directors who we believe bear the responsibility for overseeing the Company's extended period of underperformance and concerning governance missteps."

07:33 EDT FMC Corporation announces collaboration with Optibrium - FMC Corporation announced a collaboration with Optibrium, a developer of software and artificial intelligence solutions for small molecule discovery. The agreement is part of FMC's strategic plan to accelerate the discovery and commercialization of FMC's pipeline. Expanding FMC's Discovery process to include Optibrium's innovative Augmented Chemistry AI technologies will help bring new solutions to growers faster. Machine learning and AI methods will serve to identify promising compounds, optimize their properties and continue the company's focus on sustainable products.

07:29 EDT Azimut Exploration provides update on program for Pilipas Property - Azimut Exploration provides an update on the exploration program planned for the Pilipas Property in the Eeyou Istchee James Bay region of Quebec, Canada. Ophir Gold, as operator under the option agreement previously announced, has scheduled an inaugural lithium-focused surface exploration program on the Property. Expected to start on May 20th, this work will evaluate numerous priority targets identified by Ophir during a data compilation and satellite imagery analysis completed on the Property.

07:27 EDT Tilray's Breckenridge Brewery announces 'On Tap with KBCO' concert series - Breckenridge Brewery and 97.3 KBCO announced the next On Tap with KBCO featuring live music at the Breckenridge Brewery in Littleton on September 7, 2024. The charity concert series presents Cannons along with The Moss and Dehd. Ticket proceeds benefit Project C.U.R.E., a non-profit, founded in a garage in Evergreen, Colorado, Project C.U.R.E. has grown to be the largest provider of donated medical supplies and equipment to some of the toughest places in the world. With over 30,000 volunteers in seven U.S. cities, and only 3% overhead, Project C.U.R.E. is saving lives and changing the course of history around the globe. Past performers at On Tap with KBCO include Nathaniel Rateliff & The Night Sweats, Leon Bridges, The Revivalists, Cake, Dispatch, Big Head Todd and the Monsters, Marcus King Band, Caamp, Milky Chance, Michael Franti & Spearhead, The Revivalists, Shakey Graves and more.

07:24 EDT 23andMe's Lemonaid Health collabs with Petros Pharmaceuticals - Lemonaid Health, a subsidiary of 23andMe Holding (ME), is now offering Petros Pharmaceuticals, Inc.'s (PTPI), prescription erectile dysfunction medication STENDRA through its telehealth platform. Working directly with STENDRA manufacturer Petros Pharmaceuticals, Lemonaid Health is able to offer the fast-acting ED medication at improved pricing. With one in 10 men estimated to have ED at some point in their lifetime1, Lemonaid Health clinicians are able to evaluate and prescribe patients a variety of ED medications at various price points and doses.

07:20 EDT Poet Technologies announces design win, collaboration with FIT - POET Technologies announced that Foxconn Interconnect Technology, FIT, a market leader of interconnect solutions for communication infrastructure and several other large, high-growth markets, has selected POET's optical engines, which are silicon photonics integrated circuits (Silicon PIC), for its 800G and 1.6T optical transceiver modules. POET and FIT have entered into a collaboration to develop 800G and 1.6T pluggable optical transceiver modules using POET optical engines with an aim to address the growth in demand from cutting-edge AI applications and high-speed data center networks. As part of the collaboration, POET will develop and supply its silicon photonics integrated circuit optical engines based on the patented POET Optical Interposer technology and FIT, one of the world's leading manufacturers of interconnect technologies, will design and supply the high-speed pluggable optical transceivers for delivery to some of the largest end customers in the world.

07:18 EDT GXO Logistics deploys large-scale robotics solution in France - GXO Logistics, announced the deployment of a large-scale robotics solution in Europe for a major global sporting goods retailer. The solution was designed to speed order processing, increase agility to respond to seasonal volume changes and deliver efficiency savings. GXO manages a growing share of the retailer's logistics in Europe and recently began implementing automation in its solutions to enable the customer to meet demand. This first-of-its-kind solution, which is deployed across more than 12,000 square meters at the site, is part of a complete transformation of the omnichannel retailer's supply chain in the region. The solution GXO has implemented comprises about 500 autonomous mobile robots handling 70,000 bins on 5.5-meter-tall storage racks. The robots are used for picking activities and have significantly improved productivity, accuracy and safety on site. The lightweight robots are easy to transport and install, giving GXO the flexibility to quickly move them around the warehouse or deploy them to other facilities to meet seasonal changes.

07:17 EDT Neumora initiates Phase 2 study of navacaprant in bipolar depression - Neumora Therapeutics announced the initiation of a Phase 2 study evaluating the safety and efficacy of navacaprant in people with bipolar depression. Navacaprant is an oral 80 mg once-daily best-in-class kappa opioid receptor antagonist, a novel mechanism of action in development for the treatment of major depressive disorder and bipolar depression. The randomized, double-blind, placebo-controlled, Phase 2 clinical trial is designed to evaluate the safety and efficacy of navacaprant in people with depression associated with bipolar II disorder. The study will evaluate navacaprant 80 mg monotherapy in approximately 60 patients with a moderate-to-severe major depressive episode. The primary endpoint of the study is change in MADRS at Week 6, and key secondary endpoints will evaluate the impact of navacaprant on anhedonia as well as other measures. Neumora expects to report topline data from this Phase 2 study in the second half of 2025. Results from this proof-of-concept study will inform further development of navacaprant in bipolar disorder, potentially including development in broader bipolar disorder populations.

07:10 EDT Veritone announces strategic partnership with Creative Artists Agency - Veritone announced a strategic partnership with Creative Artists Agency CAA , the world's leading entertainment and sports agency, to power theCAAvault, an industry-leading synthetic media vault conceived by CAA to serve the entertainment community. As the technical launch partner for theCAAvault, Veritone is ingesting, organizing, and storing the digital talent assets, driving industry-wide innovation and delivering positive, ethical use of AI for the entertainment industry. CAA is accessing Veritone's Digital Media Hub DMH technology for theCAAvault to store the intellectual property of the participating talent's name, image and likeness. TheCAAvault offers a secure repository to store invaluable assets and all associated metadata, like synthetic counterparts, including digital scans and voice recordings. Talent has access to a unique personal vault, which enables secure storing and sharing to safeguard their name, image and likeness.

07:08 EDT Hydrofarm enters agreement with CM Fabrication to sell assets for $8.7M - On May 10, 2024, in connection with the Company's restructuring of its durable manufacturing operations, the Company entered into an agreement with CM Fabrication to sell assets relating to the production of certain durable equipment products for approximately $8.7 million. The Asset Sale is expected to close in the second quarter of 2024, subject to customary closing conditions. The Company is also entering into an exclusive supply agreement with the Buyer to provide for contract manufacturing going forward for the Company's proprietary branded Innovative Growers Equipment products. The Company will continue to sell its proprietary branded IGE products, and as a result of the transaction, the Company expects improved profitability on future IGE branded product sales due to an anticipated decrease in fixed costs. The Company estimates it will record a loss on the disposition of the tangible and intangible assets of approximately $12 million in the second quarter of 2024, upon closing of the Asset Sale. The Company plans to reinvest the net proceeds from the Asset Sale into certain permitted investments, such as capital expenditures, and/or make an offer to prepay the corresponding amount of Term Loan principal.

07:05 EDT Passage Bio announces anticipated upcoming milestones - FTD-GRN: Initiate dosing for Cohort 2 FTD-GRN patients in 1H 2024; Report 6-month safety and biomarker data from Cohort 1 patients in 2H 2024; Announce 12-month follow-up data from Cohort 1 patients in 1H 2025; Report initial safety and biomarker data from Cohort 2 patients in 1H 2025. FTD-C9orf72 and ALS: Obtain regulatory feedback on the pathway to treating FTD-C9orf72 and amyotrophic lateral sclerosis patients with PBFT02 in 2H 2024.

07:02 EDT Acumen sees cash runway into 1H27 - Cash, cash equivalents and marketable securities of $296.6 million as of Mar. 31, 2024, expected to support current clinical and operational activities into the first half of 2027.

06:40 EDT Qomolangma Acquisition receives noncompliance notification from Nasdaq - Qomolangma Acquisition announced that it has received a notice from Nasdaq stating that because the company has not yet filed its Form 10-K for the period ended December 31, 2023, the company is no longer in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission.

06:32 EDT Alibaba approves two-part dividend - The company stated, "Our board of directors has approved a two-part dividend comprised of (i) an annual regular cash dividend for fiscal year 2024 in the amount of US$0.125 per ordinary share or US$1.00 per ADS, and (ii) a one-time extraordinary cash dividend as a distribution of proceeds from disposition of certain financial investments in the amount of US$0.0825 per ordinary share or US$0.66 per ADS, in each case payable in U.S. dollars, to holders of ordinary shares and holders of ADSs, as of the close of business on June 13, 2024, Hong Kong Time and New York Time, respectively. The aggregate amount of the dividend will be approximately US$4.0 billion. For holders of ordinary shares, in order to qualify for the dividend, all valid documents for the transfers of shares accompanied by the relevant share certificates must be lodged with the Company's Hong Kong branch share registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong, not later than 4:30 p.m. on June 13, 2024, Hong Kong Time. The payment date is expected to be on or around July 3, 2024 for holders of ordinary shares and on or around July 12, 2024 for holders of ADSs."

06:25 EDT Inotiv says unable to file quarterly report on Form 10-Q on time - In a regulatory filing on Monday, Inotiv said that it is unable to file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31 within the prescribed time period without unreasonable effort and expense. The company currently expects to file the Report by May 15, 2024, within the extension period of five calendar days permitted under Rule 12b-25 of the Securities Exchange Act of 1934, as amended. As previously disclosed, the company has been cooperating with the U.S. DOJ and other authorities related to an investigation by those authorities into various matters relating to the previously disclosed execution of a search and seizure warrant at the company's Cumberland, Virginia facility. The company ceased commercial operations at the Cumberland facility in September 2022. Due to the current status of negotiations between the company and the DOJ regarding a potential resolution, as well as related actions that would need to occur in order for any such resolution to be finalized, including, without limitation, negotiations between the company and DOJ regarding mutually satisfactory resolution documents, final approvals by DOJ and the company, and depending on the terms of any final resolution with the DOJ, negotiations with certain of the company's stakeholders regarding the feasibility of such proposed resolution, the company requires additional time to complete the analysis of this subsequent event and the related accounting matters. One of the principal analyses relates to the determination of whether the current status of that matter and related considerations may meet the probable and estimable standard under applicable accounting rules to record an accrual for that matter in the quarter ended March 31, 2024 and, if so, the amount of such accrual, the long-term versus current classification of the company's outstanding debt as of March 31, 2024, the potential impact on the company's compliance with the financial covenants under the company's Credit Agreement and any ability to amend such covenants, and the company's ability to estimate and satisfy the financial obligations of any resolution. Any such accrual, depending on the amount, could result in the company's results of operations for the three and six months ended March 31, 2024 to be significantly different from the results of operations for the three and six months ended March 31, 2023. The company is working diligently to complete these analyses and finalize its financial statements as soon as possible.

06:19 EDT Fisker unable to file Form 10-Q in timely manner - In a regulatory filing, Fisker said it was unable, without unreasonable effort and expense, to complete the preparation of its Quarterly Report on Form 10-Q for the quarterly period ended March 31 by May 10. As disclosed, management identified certain material weaknesses, including that the company did not design and maintain an effective control environment commensurate with its financial reporting requirements. The company is unable to provide an estimate with respect to the timing of the filing. The company has engaged professional advisors to explore a range of strategic alternatives, including filing for bankruptcy protection in multiple jurisdictions.

06:19 EDT United Airlines expects record Memorial Day holiday - The company said, "United is ready for its busiest Memorial Day holiday ever - with a record-setting three million travelers expected to fly between May 23-28, up nearly 10% compared to last year. To help fliers navigate the crowds and jumpstart their summer vacations, United has dozens of features in its mobile app to help travelers skip lines, breeze through security, navigate to their gates, quickly check their bags and more - saving travelers up to 30 minutes on average* at the airport."

06:15 EDT Hudbay Minerals sees 2024 copper production 137K-176K tons - Sees 2024 gold production 263K-319K oz. and silver production 4.45M oz.

06:10 EDT Centerra Gold still sees 2024 total gold production 370-410 Koz. - Sees 2024 total copper production 55-65 Mlb.

06:04 EDT MediciNova receives Notice of Allowance for new patent covering MN-166 - MediciNova announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 for the treatment of chlorine-induced acute respiratory distress syndrome. Once issued, this patent is expected to expire no earlier than January 2042. The allowed claims cover the use of MN-166 for treating chlorine-induced ARDS. The allowed claims cover the use of MN-166 as a monotherapy or as a combination therapy with one or more other drugs. The allowed claims cover oral administration, intravenous administration, subcutaneous injection, intramuscular injection, and inhalation administration. The allowed claims cover a wide range of doses of MN-166, a range of different dosing frequencies, and a range of different treatment periods.

05:56 EDT Microsoft unveils Places, app that 'reimagines flexible work' - Microsoft unveils Places, an AI-powered app to help employees on Outlook and Teams better coordinate in-office time, with Copilot integration coming this year. Microsoft said: "In addition to fostering improved coordination and connection, Places optimizes the effectiveness and engagement of the workplace. Importantly, Places features are accessible across surfaces you regularly use for coordination and collaboration, like Outlook and Microsoft Teams, so flexible work coordination and connection can happen within your normal flow of work." Places will be licensed as part of Microsoft Teams Premium, contributing to the Teams vision to build a smart workplace, the company said. Reference Link

05:10 EDT On Holding sees FY24 adjusted EBITDA margin 16%-16.5% - The company said, "On has experienced continued strong demand across channels, regions and product categories in the first months of its third full financial year as a public company. Delivering a further record quarter, On has for the first time surpassed CHF 500 million in net sales in a single quarter. On continues on its Dream On strategy and looks to further increase the global awareness for the On brand, and build even closer connections with existing fans and new audiences globally through the power of a seamless omni-channel experience. Significant brand moments and exciting product launches in the coming months are expected to pave the way for the next growth phase on On's vision to be the most premium global sportswear brand. The ongoing strong brand momentum provides On with confidence to reiterate its full year expectation of at least 30% growth in net sales on a constant currency basis, while remaining prudent in light of the dynamic macroeconomic and consumer environment. At current spot rates, this implies reported net sales of at least CHF 2.29 billion in 2024. Considering the strength of On's DTC channel and commitment to ongoing profitability increases, On is further maintaining its ambition to reach a gross profit margin of around 60% and an adjusted EBITDA margin of 16.0 - 16.5% for the full year 2024."